Skip to main content

The discovery of dopamine deficiency in the parkinsonian brain

  • Conference paper

Part of the Journal of Neural Transmission. Supplementa book series (NEURALTRANS,volume 70)

Summary

This article gives a short historical account of the events and circumstances that led to the discovery of the occurrence of dopamine (DA) in the brain and its deficiency in Parkinson’s disease (PD). Some important consequences, for both the basic science and the patient, of the work on DA in the PD brain are also highlighted.

Keywords

  • Parkinsonian Brain
  • Basal Ganglion Disorder
  • Catechol Compound
  • Montreal Group
  • Perform Motor Activity

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-211-45295-0_3
  • Chapter length: 7 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   269.00
Price excludes VAT (USA)
  • ISBN: 978-3-211-45295-0
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Hardcover Book
USD   349.99
Price excludes VAT (USA)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Anden NE, Carlsson A, Dahlström A, Fuxe K, Hillarp NA, Larsson K (1964) Demonstration and mapping out of nigro-striatal dopamine neurons. Life Sci 3: 523–530

    PubMed  CAS  CrossRef  Google Scholar 

  • Barbeau A, Murphy GF, Sourkes TL (1961) Excretion of dopamine in diseases of basal ganglia. Science 133: 1706–1707

    PubMed  CAS  CrossRef  Google Scholar 

  • Barbeau A, Sourkes TL, Murphy GF (1962) Les catécholamines dans la maladie de Parkinson. In: deAjuriaguerra (ed) Monoamines et système nerveux centrale. Georg, Genève and Masson, Paris, pp 247–262

    Google Scholar 

  • Bertler Å, Rosengren E (1959a) Occurrence and distribution of dopamine in brain and other tissues. Experientia 15: 10–11

    PubMed  CAS  CrossRef  Google Scholar 

  • Bertler Å, Rosengren E (1959b) On the distribution in brain monoamines and of enzymes responsible for their formation. Experientia 15: 382–383

    PubMed  CAS  CrossRef  Google Scholar 

  • Birkmayer W, Hornykiewicz O (1961) Der L-ioxyphenylalanin (=DOPA)-Effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 73: 787–788

    PubMed  CAS  Google Scholar 

  • Birkmayer W, Hornykiewicz O (1962) Der L-Dioxyphenylalanin (=DOPA)-Effekt beim Parkinson-Syndrom des Menschen: zur Pathogenese und Behandlung der Parkinson-Akinese. Arch Psychiat Nervenkr 203: 560–574

    PubMed  CAS  CrossRef  Google Scholar 

  • Blaschko H (1957) Metabolismand storage of biogenic amines. Experientia 13: 9–12

    PubMed  CAS  CrossRef  Google Scholar 

  • Carlsson A (1964) Functional significance of druginduced changes in brain monoamine levels. In: Himwich HE, Himwich WA (eds) Biogenic amines. Elsevier, Amsterdam, pp 9–27 (Progr Brain Res 8)

    Google Scholar 

  • Carlsson A (1965) Drugs which block the storage of 5-hydroxytryptamine and related amines. In: Eichler O, Farah A (eds) 5-Hydroxytryptamine and related indolealkylamines. Springer, Berlin Heidelberg New York, pp 529–592 (Handb Exp Pharmacol vol 19)

    Google Scholar 

  • Carlsson A, Lindqvist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxy-tryptophan as reserpine antagonists. Nature 180: 1200

    PubMed  CAS  CrossRef  Google Scholar 

  • Carlsson A, Lindqvist M, Magnusson T, Waldeck B (1958) On the presence of 3-hydroxy-tyramine in brain. Science 127: 471

    PubMed  CAS  CrossRef  Google Scholar 

  • Cotzias GC, Van Woert MH, Schiffer IM (1967) Aromatic amino acids and modification of Parkinsonism. N Engl J Med 276: 374–379

    PubMed  CAS  CrossRef  Google Scholar 

  • Dahlström A, Fuxe K (1964) Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand 62[Suppl 232]

    Google Scholar 

  • Denny-Brown D (1962) The basal ganglia and their relation to disorders of movement. Oxford University Press, Oxford

    Google Scholar 

  • Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 38: 1236–1239

    PubMed  CAS  CrossRef  Google Scholar 

  • Hardy J, Langston WJ (2004) How many pathways are there to nigral death? Ann Neurol 56: 316–318

    PubMed  CrossRef  Google Scholar 

  • Hassler R (1938) Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus. J Psychol Neurol 48: 387–476

    Google Scholar 

  • Hassler R (1967) Private communication to O. Hornykiewicz. Letter dated February 9, 1967

    Google Scholar 

  • Holtz P, Balzer H, Westermann E, Wezler E (1957) Beeinflussung der Evipannarkose durch Reserpin, Iproniazid und biogene Amine. Arch Exp Path Pharmakol 231: 333–348

    CAS  Google Scholar 

  • Holzer G, Hornykiewicz O (1959) Über den Dopamin-(Hydroxytyramin-) Stoffwechsel im Gehirn der Ratte. Naunyn Schmiedebergs Arch Exp Path Pharmacol 237: 27–33

    CAS  Google Scholar 

  • Hornykiewicz O (1958) The action of dopamine on the arterial pressure of the guinea pig. Br J Pharmacol 13: 91–94

    CAS  Google Scholar 

  • Hornykiewicz O (1963) Die topische Lokalisation und das Verhalten von Noradrenalin und Dopamin (3-Hydroxytyramin) in the Substantia nigra des normalen und Parkinsonkranken Menschen. Wien Klin Wochenschr 75: 309–312

    PubMed  CAS  Google Scholar 

  • Hornykiewicz O (2001a) Brain dopamine: a historical perspective. In: Di Chiara G (ed) Dopamine in the CNS I. Springer, Berlin Heidelberg, pp 1–22 (Handb Exp Pharmacol vol 154/I)

    Google Scholar 

  • Hornykiewicz O (2001b) How L-DOPA was discovered as a drug for Parkinson’s disease 40 years ago. Wien Klin Wochenschr 113: 855–862

    PubMed  CAS  Google Scholar 

  • Hornykiewicz O (2002a) Dopamine and Parkinson’s disease. A personal view of the past, the present, and the future. Adv Neurol 86: 1–11

    Google Scholar 

  • Hornykiewicz O (2002b) Dopamine miracle: from brain homogenate to dopamine replacement. Mov Disord 17: 501–508

    PubMed  CrossRef  Google Scholar 

  • Jasper HH (1970) Neurophysiological mechanisms in parkinsonism. In: Barbeau A, McDowell FH (eds) L-Dopa and parkinsonism. FA Davis, Philadelphia, pp 408–411

    Google Scholar 

  • Jung R, Hassler R (1960) The extrapyramidal motor systems. In: Field J, Magoun HW, Hall VE (eds) Handbook of Physiology, sect 1. Neurophysiology, vol II. American Physiological Society, Washington DC, pp 863–927

    Google Scholar 

  • Montagu KA (1957) Catechol compounds in rat tissues and in brains of different animals. Nature 180: 244–245

    PubMed  CAS  CrossRef  Google Scholar 

  • Poirier LJ, Sourkes TL (1965) Influence of the substantia nigra on the catecholamine content of the striatum. Brain 88: 181–192

    PubMed  CAS  Google Scholar 

  • Raab W, Gigee W (1951) Concentration and distribution of “encephalin” in the brain of humans and animals. Proc Soc Exp Biol Med 76: 97–100

    PubMed  CAS  Google Scholar 

  • Sano I (1962) Private communication to O. Hornykiewicz. Letter dated March 20, 1962

    Google Scholar 

  • Sano I (2000) Biochemistry of the extrapyramidal system. Parkinsonism Relat Disord 6: 3–6

    CrossRef  CAS  PubMed  Google Scholar 

  • Sano I, Gamo T, Kakimoto Y, Taniguchi K, Takesada M, Nishinuma K (1959) Distribution of catechol compounds in human brain. Biochim Biophys Acta 32: 586–587

    PubMed  CAS  CrossRef  Google Scholar 

  • Sourkes TL (2000) How dopamine was recognised as a neurotransmitter: a personal view. Parkinsonism Relat Disord 6: 63–67

    PubMed  CrossRef  Google Scholar 

  • Vogt M (1952) Die Verteilung pharmakologisch aktiver Substanzen im Zentralnervensystem. Klin Wochenschr 30: 907–908

    CrossRef  Google Scholar 

  • Vogt M (1954) The concentration of sympathin in different parts of the central nervous system under normal conditions and after the administration of drugs. J Physiol 123: 451–481

    PubMed  CAS  Google Scholar 

  • Vogt M (1973) Functional aspects of the role of catecholamines in the central nervous system. Br Med Bull 29: 168–172

    PubMed  CAS  Google Scholar 

  • Ward AA (1970) Physiological implications in the dyskinesias. In: Barbeau A, McDowell FH (eds) L-Dopa and parkinsonism. FA Davis, Philadelphia, pp 151–159

    Google Scholar 

  • Weber G (1952) Zum Cholinesterasegehalt des Gehirns bei Hirntumoren und bei Parkinsonismus. Bull Schweiz Akad Med Wiss 8: 263–268

    PubMed  CAS  Google Scholar 

  • Weil-Malherbe H, Bone AD (1957) Intracellular distribution of catecholamines in the brain. Nature 180: 1050–1051

    PubMed  CAS  CrossRef  Google Scholar 

  • Weil-Malherbe H, Bone AD (1958) Effect of reserpine on the intracellular distribution of catecholamines in the brain stem of the rabbit. Nature 181: 1474–1475

    PubMed  CAS  CrossRef  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2006 Springer-Verlag

About this paper

Cite this paper

Hornykiewicz, O. (2006). The discovery of dopamine deficiency in the parkinsonian brain. In: Riederer, P., Reichmann, H., Youdim, M.B.H., Gerlach, M. (eds) Parkinson’s Disease and Related Disorders. Journal of Neural Transmission. Supplementa, vol 70. Springer, Vienna . https://doi.org/10.1007/978-3-211-45295-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-211-45295-0_3

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-28927-3

  • Online ISBN: 978-3-211-45295-0

  • eBook Packages: MedicineMedicine (R0)